Skip to main navigation Skip to search Skip to main content

Mechanism-based inactivator of isocitrate lyases 1 and 2 from Mycobacterium tuberculosis

  • Truc V. Pham
  • , Andrew S. Murkin
  • , Margaret M. Moynihan
  • , Lawrence Harris
  • , Peter C. Tyler
  • , Nishant Shetty
  • , James C. Sacchettini
  • , Hsiao ling Huang
  • , Thomas D. Meek
  • Texas A&M University
  • SUNY Buffalo
  • Johnson & Johnson
  • Victoria University of Wellington
  • Fujifilm Diosynth Biotechnologies Texas
  • Albany Molecular Research, Inc.

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

Isocitrate lyase (ICL, types 1 and 2) is the first enzyme of the glyoxylate shunt, an essential pathway for Mycobacterium tuberculosis (Mtb) during the persistent phase of human TB infection. Here, we report 2-vinyl-D-isocitrate (2-VIC) as a mechanism-based inactivator of Mtb ICL1 and ICL2. The enzyme-catalyzed retro-aldol cleavage of 2-VIC unmasks a Michael substrate, 2-vinylglyoxylate, which then forms a slowly reversible, covalent adduct with the thiolate form of active-site Cys191. 2-VIC displayed kinetic properties consistent with covalent, mechanism-based inactivation of ICL1 and ICL2 with high efficiency (partition ratio, <1). Analysis of a complex of ICL1:2-VIC by electrospray ionization mass spectrometry and X-ray crystallography confirmed the formation of the predicted covalent S-homopyruvoyl adduct of the active-site Cys191.

Original languageEnglish
Pages (from-to)7617-7622
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume114
Issue number29
DOIs
StatePublished - Jul 18 2017

Keywords

  • 2-vinyl isocitrate
  • Covalent adduct
  • Isocitrate lyase
  • Mechanism-based inactivation
  • Tuberculosis

Fingerprint

Dive into the research topics of 'Mechanism-based inactivator of isocitrate lyases 1 and 2 from Mycobacterium tuberculosis'. Together they form a unique fingerprint.

Cite this